Measures · D05 in 2024 · Part D · DD3 Member Experience with the Drug Plan
Rating of Drug Plan
Drug PlanMember ExperienceSource: CAHPS
- What it measures
- Percent of the best possible score the plan earned from members who rated the prescription drug plan.
- How it's calculated
- This case-mix adjusted measure is used to assess members' overall view of their prescription drug plan. The Consumer Assessment of Healthcare Providers and Systems (CAHPS) score uses the mean of the distribution of responses converted to a scale from 0 to 100. The score shown is the percentage of the best possible score each contract earned.
- Data source
- CAHPS CAHPS Survey Questions (question numbers vary depending on survey type): • Using any number from 0 to 10, where 0 is the worst prescription drug plan possible and 10 is the best prescription drug plan possible, what number would you use to rate your prescription drug plan?
- Measurement period
- 03/2023 – 06/2023
- Better when
- Higher
- Weight
- 4 (Patients’ Experience and Complaints Measure)
- Star assignment
- Relative Distribution and Significance Testing
- Case-mix adjusted
- Yes
- In improvement measure
- Yes
- Used in CAI
- No
- Notes
- CAHPS Survey results were sent to each contract's Medicare Compliance Officer in August 2023. These reports provide further explanation of the CAHPS scoring methodology and provide detailed information on why a specific rating was assigned.
- Disaster policy
- Higher measure star (2023-2024) for contracts with 25% or more enrolled affected by 2022 disasters.
From the 2024 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 86 | 86 | 0 |
| 4★ | MA-PD | 87 | 87 | 0 |
| 5★ | MA-PD | 89 | 89 | 0 |
| 2★ | PDP | 82 | 82 | 0 |
| 3★ | PDP | 83 | 83 | 0 |
| 4★ | PDP | 86 | 86 | 0 |
| 5★ | PDP | 88 | 88 | 0 |
2024 star distribution
Not rated: Plan too small to be measured (150); Plan too new to be measured (96); No data available (29); Plan not required to report measure (5)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 to < 89 | >= 89 |
| 2027 | PDP | < 82 | >= 82 to < 83 | >= 83 to < 86 | >= 86 to < 88 | >= 88 |
| 2026 | MA-PD | < 85 | >= 85 to < 86 | >= 86 to < 88 | >= 88 to < 89 | >= 89 |
| 2026 | PDP | < 82 | >= 82 to < 83 | >= 83 to < 86 | >= 86 to < 88 | >= 88 |
| 2025 | MA-PD | < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 to < 89 | >= 89 |
| 2025 | PDP | < 79 | >= 79 to < 82 | >= 82 to < 85 | >= 85 to < 87 | >= 87 |
| 2024 | MA-PD | < 84 | >= 84 to < 85 | >= 85 to < 87 | >= 87 to < 89 | >= 89 |
| 2024 | PDP | < 80 | >= 80 to < 81 | >= 81 to < 83 | >= 83 to < 87 | >= 87 |
| 2023 | MA-PD | < 83 | >= 83 to < 85 | >= 85 to < 87 | >= 87 to < 88 | >= 88 |
| 2023 | PDP | < 79 | >= 79 to < 80 | >= 80 to < 83 | >= 83 to < 87 | >= 87 |
| 2022 | MA-PD | < 84 | >= 84 to < 85 | >= 85 to < 87 | >= 87 to < 88 | >= 88 |
| 2022 | PDP | < 80 | >= 80 to < 82 | >= 82 to < 84 | >= 84 to < 87 | >= 87 |
| 2021 | MA-PD | < 83 | >= 83 to < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 |
| 2021 | PDP | < 80 | >= 80 to < 81 | >= 81 to < 83 | >= 83 to < 87 | >= 87 |
| 2020 | MA-PD | < 83 | ? 83 to < 84 | ? 84 to < 86 | ? 86 to < 87 | ? 87 |
| 2020 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 83 | ? 83 to < 87 | ? 87 |
| 2019 | MA-PD | < 82 | ? 82 to < 83 | ? 83 to < 85 | ? 85 to < 87 | ? 87 |
| 2019 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 84 | ? 84 to < 86 | ? 86 |
| 2018 | MA-PD | < 81 | ? 81 to < 83 | ? 83 to < 85 | ? 85 to < 86 | ? 86 |
| 2018 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 83 | ? 83 to < 87 | ? 87 |
| 2017 | MA-PD | < 80 | ? 80 to < 82 | ? 82 to < 84 | ? 84 to < 86 | ? 86 |
| 2017 | PDP | < 79 | ? 79 to < 80 | ? 80 to < 83 | ? 83 to < 86 | ? 86 |
| 2016 | MA-PD | < 80 | ? 80 to < 82 | ? 82 to < 84 | ? 84 to < 86 | ? 86 |
| 2016 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 82 | ? 82 to < 86 | ? 86 |
| 2015 | MA-PD | < 82% | ? 82% to < 83% | ? 83% to < 84% | ? 84% to < 87% | ? 87% |
| 2015 | PDP | < 80% | ? 80% to < 81% | * | ? 81% to < 86% | ? 86% |
Lowest-scoring contracts, 2024
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S2874 Humana | Humana Inc. | — | 71 | 1 | 0 | 12 | 0% |
| H6605 Wellcare by ‘Ohana Health Plan | Centene Corporation | — | 77 | 1 | — | 10 | 0% |
| H0088 Wellcare | Centene Corporation | — | 77 | 1 | — | 10 | 0% |
| H4801 Blue Cross and Blue Shield of OK, TX | Health Care Service Corporation | — | 78 | 1 | — | 9 | 0% |
| H6067 CareFirst BlueCross BlueShield Medicare Advantage | CareFirst, Inc. | — | 78 | 1 | 0 | 9 | 0% |
| H9219 AMH Health | Elevance Health, Inc. | 194 | 80 | 1 | — | 7 | 1% |
| H5439 Wellcare | Centene Corporation | 19,153 | 80 | 1 | 0 | 7 | 1% |
| H0422 UCare | UCare Minnesota | — | 80 | 1 | — | 7 | 1% |
| H3206 Presbyterian Insurance Company, Inc. | Presbyterian Healthcare Services | — | 80 | 1 | −1 | 7 | 1% |
| H1914 Wellcare | Centene Corporation | 10,826 | 80 | 1 | 0 | 7 | 1% |
| H1353 Wellcare | Centene Corporation | — | 80 | 1 | −1 | 7 | 1% |
| H8552 Anthem Blue Cross Life and Health Insurance Company | Elevance Health, Inc. | 1,065 | 80 | 1 | 0 | 7 | 1% |
| H4213 Arkansas Blue Medicare | USAble Mutual Insurance Company | 2,258 | 81 | 1 | 0 | 6 | 2% |
| H9976 Wellcare by Allwell | Centene Corporation | — | 81 | 1 | — | 6 | 2% |
| H1732 ANTHEM BLUE CROSS AND BLUE SHIELD HP | Elevance Health, Inc. | — | 81 | 1 | 0 | 6 | 2% |
| H3170 Blue Cross and Blue Shield of Nebraska | Blue Cross Blue Shield of Nebraska | 6,760 | 81 | 1 | −1 | 6 | 2% |
| H8432 Anthem Blue Cross and Blue Shield HP | Elevance Health, Inc. | 43,447 | 81 | 1 | 0 | 6 | 2% |
| H9900 Wellcare | Centene Corporation | — | 81 | 1 | — | 6 | 2% |
| H1666 Blue Cross and Blue Shield of NM, TX | Health Care Service Corporation | 15,741 | 81 | 1 | −1 | 6 | 2% |
| S6946 Clear Spring Health | Group 1001 | — | 76 | 1 | 0 | 7 | 2% |
| H5926 Molina Healthcare of Michigan | Molina Healthcare, Inc. | 15,303 | 82 | 1 | −2 | 5 | 3% |
| R5329 UnitedHealthcare | UnitedHealth Group, Inc. | — | 82 | 1 | −1 | 5 | 3% |
| H6193 Wellcare | Centene Corporation | — | 82 | 1 | — | 5 | 3% |
| H3251 Blue Cross and Blue Shield of New Mexico | Health Care Service Corporation | 19,880 | 82 | 1 | 0 | 5 | 3% |
| H5823 Molina Healthcare of Washington, Inc. | Molina Healthcare, Inc. | 13,098 | 82 | 1 | −1 | 5 | 3% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D05 | Rating of Drug Plan | 03/2026 – 06/2026 | 2 | CAHPS |
| 2026 | D05 | Rating of Drug Plan | 03/2025 – 05/2025 | 2 | CAHPS |
| 2025 | D05 | Rating of Drug Plan | 03/2024 – 06/2024 | 4 | CAHPS |
| 2024 | D05 | Rating of Drug Plan | 03/2023 – 06/2023 | 4 | CAHPS |
| 2023 | D05 | Rating of Drug Plan | 03/2022 – 06/2022 | 4 | CAHPS |
| 2022 | D05 | Rating of Drug Plan | 03/2021 – 05/2021 | 2 | CAHPS |
| 2021 | D07 | Rating of Drug Plan | 03/2019 – 05/2019 | 2 | CAHPS |
| 2020 | D07 | Rating of Drug Plan | 03/2019 – 05/2019 | 1.5 | CAHPS |
| 2019 | D07 | Rating of Drug Plan | 03/2018 – 06/2018 | 1.5 | CAHPS |
| 2018 | D08 | Rating of Drug Plan | 03/2017 – 06/2017 | 1.5 | CAHPS |
| 2017 | D08 | Rating of Drug Plan | 02/2016 – 08/2016 | 1.5 | CAHPS |
| 2016 | D08 | Rating of Drug Plan | 02/15/2015 - 05/31/2015 | 1.5 | CAHPS |
| 2015 | D06 | Rating of Drug Plan | 02/15/2014 - 05/31/2014 | 1.5 | CAHPS |